Adagio presses forward with their FDA pitch for Covid antibody — despite Omicron flaws
Adagio, the Tillman Gerngross biotech whose $750 million plan to build a pan-coronavirus antibody seemingly fell apart in the face of Omicron, is back again pleading its case.
The company released data from its pivotal trials Wednesday, announcing that its antibody adintrevimab reduced the risk of hospitalization or death in participants with mild to moderate Covid-19 by 66%, including a 77% reduction in patients who were treated within 3 days of symptom onset.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.